July 2, 2021 Journal article Open Access

Alshafie, Walaa; Fotouhi, Maryam; Southern, Kathleen; McPherson, Peter S.; Laflamme, Carl

Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Alshafie, Walaa</dc:creator>
  <dc:creator>Fotouhi, Maryam</dc:creator>
  <dc:creator>Southern, Kathleen</dc:creator>
  <dc:creator>McPherson, Peter S.</dc:creator>
  <dc:creator>Laflamme, Carl</dc:creator>
  <dc:date>2021-07-02</dc:date>
  <dc:description>Head to head comparison of available commercial antibodies against Ataxin-2 by immunoblot (Western blot), immunoprecipitation and immunofluorescence.

This work is part of the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.</dc:description>
  <dc:identifier>https://zenodo.org/record/5061824</dc:identifier>
  <dc:identifier>10.5281/zenodo.5061824</dc:identifier>
  <dc:identifier>oai:zenodo.org:5061824</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>doi:10.5281/zenodo.5061823</dc:relation>
  <dc:relation>url:https://zenodo.org/communities/openlabnotebooks</dc:relation>
  <dc:relation>url:https://zenodo.org/communities/sgc-opennotebook</dc:relation>
  <dc:relation>url:https://zenodo.org/communities/ycharos</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>https://creativecommons.org/licenses/by/4.0/legalcode</dc:rights>
  <dc:subject>Ataxin-2</dc:subject>
  <dc:subject>Spinocerebellar ataxia type 2 protein</dc:subject>
  <dc:subject>Trinucleotide repeat-containing gene 13 protein</dc:subject>
  <dc:subject>ATXN2</dc:subject>
  <dc:subject>atxn2</dc:subject>
  <dc:subject>Q99700</dc:subject>
  <dc:subject>antibody characterization</dc:subject>
  <dc:subject>antibody validation</dc:subject>
  <dc:subject>Amyotrophic lateral sclerosis</dc:subject>
  <dc:subject>ALS-RAP</dc:subject>
  <dc:title>Antibody Characterization Report for Ataxin-2</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>